Liquidia Corporation
NASDAQ:LQDABiotechnology
+$0.23 today
- Market cap
- $5.08B
- Beta
- 0.59
- P/E (TTM)
- 271.8
- EPS (TTM)
- $0.25
Volume 1.22M
Average 1.50M
LQDA EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Liquidia CorporationNASDAQ: LQDA
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) turns positive
Q2 FY2026 EPS (Diluted) was $0.74, compared with -$0.49 a year earlier. Trailing-twelve-month EPS (Diluted) was $1.37.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 3 analysts of -$0.13 (+84.3%) for the fiscal year ending Dec 2026, a step up from the +51.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $0.74+42.3% QoQ
- Last fiscal yearDec 2025
- -$0.8+51.8% YoY
- LTMJun 2026
- $1.37+181.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +251.0% | +2446.1% | +2195.0 pp |
| 1 year | +51.8% | +84.3% | +32.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (0.80) USD
- Year-over-year change
- +51.8%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.80) | +51.8% |
| FY2024 | 2024-12-31 | (1.66) | -37.2% |
| FY2023 | 2023-12-31 | (1.21) | -80.6% |
| FY2022 | 2022-12-31 | (0.67) | +4.3% |
| FY2021 | 2021-12-31 | (0.70) | — |
EPS (Diluted) vs competitors
How LQDA compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +181.0% is the highest of 4, against a peer median of +8.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $27.91 USD | +8.9% | +22.9% | |
| LTM Jun 2026 | $1.37 USD | +181.0% | — | |
| LTM Jun 2026 | -$4.11 USD | +28.0% | — | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | -SEK 9.4 SEK | +3.9% | — |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — |
| Peer median (excluding LQDA) | — | +8.9% | +22.9% | |
Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.85M | 15.94M | 17.49M | 14M | 158.32M |
| Cost of Revenue | 3.02M | 2.86M | 2.89M | 5.88M | 13.24M |
| Gross Profit | 9.83M | 13.08M | 14.6M | 8.12M | 145.08M |
| Gross Margin | 76.5% | 82.1% | 83.5% | 58.0% | 91.6% |
| Research & Development | 20.52M | 19.44M | 43.24M | 47.84M | 39.28M |
| Selling, General & Admin | 23.11M | 32.41M | 44.74M | 81.57M | 157.18M |
| Operating Expenses | 43.63M | 51.85M | 87.98M | 129.41M | 196.45M |
| Depreciation & Amortization | 5.61M | 3.65M | 2.18M | 2.2M | 1.53M |
| EBITDA | (28.21M) | (35.03M) | (70.05M) | (115.71M) | (43.22M) |
| EBITDA Margin | -219.4% | -219.8% | -400.6% | -826.7% | -27.3% |
| Operating Income | (33.8M) | (38.77M) | (73.38M) | (121.29M) | (51.38M) |
| Operating Margin | -263.0% | -243.3% | -419.6% | -866.6% | -32.5% |
| Interest Income | 33K | 1.09M | 3.47M | 7.65M | 6.62M |
| Interest Expense | 762K | 2.34M | 6.27M | 12.49M | 24.17M |
| Other Income / Expenses | (782K) | (2.25M) | (5.12M) | (9.1M) | (17.55M) |
| Income Before Tax | (34.58M) | (41.02M) | (78.5M) | (130.39M) | (68.92M) |
| Pre-Tax Margin | -269.0% | -257.4% | -448.9% | -931.7% | -43.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (34.58M) | (41.02M) | (78.5M) | (130.39M) | (68.92M) |
| Net Margin | -269.0% | -257.4% | -448.9% | -931.7% | -43.5% |
| EPS (Basic) | (0.70) | (0.67) | (1.21) | (1.66) | (0.80) |
| EPS (Diluted) | (0.70) | (0.67) | (1.21) | (1.66) | (0.80) |
| Weighted Avg Shares | 49.68M | 60.96M | 64.99M | 78.71M | 86.06M |
| Weighted Avg Shares (Diluted) | 49.68M | 60.96M | 64.99M | 78.71M | 86.06M |
Liquidia Corporation
NASDAQ:LQDA
Intrinsic Alpha fair value
Locked
Current Price
$56.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.